Miplyffa Capsule
NDC Package 72542-147-01
Package Information
Miplyffa (arimoclomol citrate) capsules is mIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older. This formulation utilizes a capsule delivery system. Marketed by Acer Therapeutics Inc., this product is identified by NDC 72542-147 and is authorized under FDA application NDA214927.
Identification & Billing
- RxCUI: 2694288 - arimoclomol 124 MG Oral Capsule
- RxCUI: 2694288 - arimoclomol 124 MG (equivalent to 200 MG arimoclomol citrate) Oral Capsule
- RxCUI: 2694294 - MIPLYFFA 124 MG Oral Capsule
- RxCUI: 2694294 - arimoclomol 124 MG Oral Capsule [Miplyffa]
- RxCUI: 2694294 - Miplyffa 124 MG (equivalent to 200 MG arimoclomol citrate) Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72542 - Acer Therapeutics Inc.
- 72542-147 - Miplyffa
- 72542-147-01 - 1 BOTTLE in 1 CARTON / 90 CAPSULE in 1 BOTTLE
- 72542-147 - Miplyffa
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72542-147-01 identifies a specific commercial package of 1 bottle in 1 carton / 90 capsule in 1 bottle of Miplyffa, a human prescription drug labeled by Acer Therapeutics Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This capsule is formulated for oral use and contains arimoclomol citrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Acer Therapeutics Inc. on September 20, 2024. The current certification is valid through December 31, 2027.
How is this Acer Therapeutics Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72542014701. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.